The Department of Defense is seeking to develop antiviral therapeutic medical countermeasures effective against naturally occurring or biologically engineered Filoviridae viruses.
The effort is managed by the Emerging Infectious Diseases Therapeutics (EID Tx) program under the Joint Product Manager Biological Defense Therapeutics (JPdM-BDTX).
EID Tx is specifically interested in an antiviral therapeutic that addresses one or more Filoviridae (Ebola Zaire, Ebola Sudan, Marburg) with the potential of addressing additional Biological Warfare Agents beyond the Filoviridae indication targeting the following virus families:
- Arenaviridae – Lassa Fever, Junin
- Bunyaviridae – Hantaan
- Filoviridae – Tai Forest, Bundibugyo
- Togaviridae – Eastern Equine Encephalitis, Western Equine Encephalitis, Venezuelan Equine Encephalitis
The program is soliciting capability statements under a new Request for Information (RFI). A similar RFI was posted April 2, 2014 under Announcement Number HDTRA1-14-JPM-0001 and previous responders are requested by the DoD to send confirmation of continued interest.
Further details are available via Solicitation Number: W911QY-15-S-BDTX. The response deadline is Feb. 26, 2015.
